In This Section
Issues & Advocacy
SNMMI's mission with regard to health policy and regulatory affairs is to enhance its credibility, advance its issues, and through leadership become a valued partner among public policy stakeholders.
LATEST NEWS
- May 16, 2022 —
SNMMI & Partners Urge Congress to Support Increased Federal Research Funding
SNMMI and 368 members of the Ad Hoc Group for Medical Research sent a letter to Congress requesting that the Labor-HHS Subcommittee be allocated sufficient funding to allow for investment in NIH and other agencies that promote the health of our nation. The letter also urged Congress to work expeditiously to complete FY 2023 appropriations in a timely manner. - April 28, 2022 —
SNMMI and Partners Request a Hearing for the FIND Act
This week, SNMMI and over 70 organizations sent a letter to House Energy and Commerce and Ways and Means Committee Leadership requesting a hearing on the Facilitating Innovative Nuclear Diagnostics (FIND) Act. - March 28, 2022 —
SNMMI Hosts AI and Patient Access Summits
On March 21-23, SNMMI hosted two summits in Bethesda, MD, on Artificial Intelligence and Barriers to Patient Access. The aim of the summits—the first of their kind for the society—was to bring together thought leaders to discuss current obstacles in the field of nuclear medicine and provide solutions. Read the highlights. - March 11, 2022 —
New Issue of Clinical Trials Newsletter "Pathways" Now Available
The February 2022 issue of the SNMMI Clinical Trials Network newsletter, Pathways, is now available online. - March 4, 2022 —
SNMMI Supports ARPA-H Act
SNMMI signed on as a supporting organization to the Advanced Research Project Agency Health (ARPA-H) Act and offered to be a resource as the bill's sponsor continues to refine the legislative text. - February 18, 2022 —
SNMMI Congratulates FDA Commissioner Califf
SNMMI congratulates Robert Califf, MD, on his confirmation as the 25th Commissioner of the U.S. Food and Drug Administration. - February 17, 2022 —
SNMMI Advocates for Expanded Coverage & Reimbursement of Amyloid PET
When CMS issued a national coverage determination analysis for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease, SNMMI took action. - February 7, 2022 —
NRC Votes to Establish Requirements for Rubidium-82 Generators and Emerging Medical Technologies
Along with voting on training and experience requirements for authorized users, the Nuclear Regulatory Commission (NRC) approved of initiating rulemaking to modernize 10 Code of Federal Regulations (CFR) Part 35.
Click For More Government Relations News